We are investing in clinical activities and intellectual property management. Our clinical-stage first-in-class indication drug mocravimod has entered a registration-enabling Phase III.
In addition, we plan to investigate mocravimod in a CAR-T exploratory clinical study.
Mocravimod was tested in over 400 human subjects, including extensive Phase I studies, Phase IIa studies in autoimmune indications (Ulcerative Colitis, subacute cutaneous Lupus Erythematosus and Crohn’s Disease) and in a Phase Ib/IIa Hematopoietic Cell Transplant (HCT) study to treat hematological malignancies.
